<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/714"/><api:result><api:object category="publication" id="714" last-affected-when="2024-03-14T05:39:47.09+00:00" last-modified-when="2024-03-14T05:39:47.09+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/714" created-when="2010-05-17T13:46:27.693+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>false</api:ever-approved><api:reporting-date-1>1999-12-25</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="94412" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0032763013" last-modified-when="2023-08-16T04:21:18.85+01:00"><api:citation-count>39</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Many studies have highlighted the role played by matrix metalloproteinases MMP-2 and -9, by serine proteases uPA and plasmin in tumor cell invasion. This study investigates the impact of the MMP-inhibitor Batimastat and/or the serine protease inhibitor Aprotinin on the in vitro proteolytic activity and in vivo invasive behavior the of esophageal (OC1) and ovarian (OVCAR-3) carcinoma cells. In presence and absence of inhibitors proteolytic activity of the tumor cells was determined by caseinolytic and collagenolytic in vitro assays and tumor cell invasion by intraperitoneal inoculation of the tumor cells into nude mice. In vitro, Aprotinin tested alone or in combination with Batimastat, efficiently inhibited degradation of collagen IV and casein by the tumor cells. Batimastat alone had no effect on caseinolytic activities and only partially blocked collagen-type-IV-degradation by the tumor cells. In vivo, Aprotinin tested alone or in combination with Batimastat did not prevent tumor cell invasion. Treatment of tumor bearing mice with Batimastat significantly inhibited tumor growth but promoted tumor cell invasion into the liver. Our findings demonstrate that the inhibition pattern of cellular proteolytic activity achieved in vitro by a serine protease and an MMP inhibitor may lead to predictions that are not necessarily verified in vivo and may even have adverse effects.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Technische Universität München</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address><api:address iso-country-code="IE"><api:line type="organisation">University College Cork</api:line><api:line type="city">Cork</api:line><api:line type="country">Ireland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6601986106</api:identifier></api:identifiers></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Technische Universität München</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6506306493</api:identifier></api:identifiers></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Roche Diagnostics GmbH</api:line><api:line type="city">Penzberg</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004428380</api:identifier></api:identifiers></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="IE"><api:line type="organisation">University College Cork</api:line><api:line type="city">Cork</api:line><api:line type="country">Ireland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7201994248</api:identifier></api:identifiers></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="IE"><api:line type="organisation">University College Cork</api:line><api:line type="city">Cork</api:line><api:line type="country">Ireland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7006875637</api:identifier></api:identifiers></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Technische Universität München</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7401931237</api:identifier></api:identifiers></api:person><api:person><api:last-name>Krüger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Technische Universität München</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address><api:address iso-country-code="DE"><api:line type="organisation">Klinikum Rechts der Isar</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35460630800</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10628317</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5 B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anticancer Research</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>25</api:day><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record><api:record format="native" id="714" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10628317" last-modified-when="2022-11-22T23:24:33.037+00:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Many studies have highlighted the role played by matrix metalloproteinases MMP-2 and -9, by serine proteases uPA and plasmin in tumor cell invasion. This study investigates the impact of the MMP-inhibitor Batimastat and/or the serine protease inhibitor Aprotinin on the in vitro proteolytic activity and in vivo invasive behavior the of esophageal (OC1) and ovarian (OVCAR-3) carcinoma cells. In presence and absence of inhibitors, proteolytic activity of the tumor cells was determined by caseinolytic and collagenolytic in vitro assays and tumor cell invasion by intraperitoneal inoculation of the tumor cells into nude mice. In vitro, Aprotinin, tested alone or in combination with Batimastat, efficiently inhibited degradation of collagen IV and casein by the tumor cells. Batimastat alone had no effect on caseinolytic activities and only partially blocked collagen-type-IV-degradation by the tumor cells. In vivo, Aprotinin tested alone or in combination with Batimastat did not prevent tumor cell invasion. Treatment of tumor bearing mice with Batimastat significantly inhibited tumor growth but promoted tumor cell invasion into the liver. Our findings demonstrate that the inhibition pattern of cellular proteolytic activity achieved in vitro by a serine protease and an MMP inhibitor may lead to predictions that are not necessarily verified in vivo and may even have adverse effects.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="full">Klinische Forschergruppe, Technischen Universität München, Germany.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krüger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10628317</api:text></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anticancer Res</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adenocarcinoma</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Aprotinin</api:keyword><api:keyword scheme="mesh">Collagen</api:keyword><api:keyword scheme="mesh">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase Inhibitors</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Mice, Nude</api:keyword><api:keyword scheme="mesh">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Phenylalanine</api:keyword><api:keyword scheme="mesh">Plasminogen</api:keyword><api:keyword scheme="mesh">Plasminogen Activators</api:keyword><api:keyword scheme="mesh">Protease Inhibitors</api:keyword><api:keyword scheme="mesh">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword><api:keyword scheme="mesh">Tumor Cells, Cultured</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Greece</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>18</api:day><api:month>2</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record><api:record format="native" id="882009" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10628317" last-modified-when="2021-06-22T17:41:34.813+01:00"><api:citation-count>17</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Many studies have highlighted the role played by matrix metalloproteinases MMP-2 and -9, by serine proteases uPA and plasmin in tumor cell invasion. This study investigates the impact of the MMP-inhibitor Batimastat and/or the serine protease inhibitor Aprotinin on the in vitro proteolytic activity and in vivo invasive behavior the of esophageal (OC1) and ovarian (OVCAR-3) carcinoma cells. In presence and absence of inhibitors, proteolytic activity of the tumor cells was determined by caseinolytic and collagenolytic in vitro assays and tumor cell invasion by intraperitoneal inoculation of the tumor cells into nude mice. In vitro, Aprotinin, tested alone or in combination with Batimastat, efficiently inhibited degradation of collagen IV and casein by the tumor cells. Batimastat alone had no effect on caseinolytic activities and only partially blocked collagen-type-IV-degradation by the tumor cells. In vivo, Aprotinin tested alone or in combination with Batimastat did not prevent tumor cell invasion. Treatment of tumor bearing mice with Batimastat significantly inhibited tumor growth but promoted tumor cell invasion into the liver. Our findings demonstrate that the inhibition pattern of cellular proteolytic activity achieved in vitro by a serine protease and an MMP inhibitor may lead to predictions that are not necessarily verified in vivo and may even have adverse effects.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="DE"><api:line type="full">Klinische Forschergruppe, Technischen Universität München, Germany.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krüger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1791-7530</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10628317</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anticancer research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Tumor Cells, Cultured</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Mice, Nude</api:keyword><api:keyword scheme="mesh">Adenocarcinoma</api:keyword><api:keyword scheme="mesh">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword><api:keyword scheme="mesh">Collagen</api:keyword><api:keyword scheme="mesh">Plasminogen</api:keyword><api:keyword scheme="mesh">Plasminogen Activators</api:keyword><api:keyword scheme="mesh">Phenylalanine</api:keyword><api:keyword scheme="mesh">Aprotinin</api:keyword><api:keyword scheme="mesh">Protease Inhibitors</api:keyword><api:keyword scheme="mesh">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase Inhibitors</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>11</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record><api:record format="native" id="2682885" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1074574058" last-modified-when="2023-12-22T07:25:06.95+00:00"><api:citation-count>31</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DE"><api:line type="organisation">Technical University of Munich</api:line><api:line type="city">Munich</api:line><api:line type="country">Germany</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0737553565.51</api:identifier></api:identifiers></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0661500611.98</api:identifier></api:identifiers></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0655153272.73</api:identifier></api:identifiers></api:person><api:person><api:last-name>Krüger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01334512522.20</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10628317</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anticancer Research</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Ovarian Cancer</api:keyword><api:keyword scheme="hrcs-rac">2.1 Biological and endogenous factors</api:keyword><api:keyword scheme="hrcs-rac">2 Aetiology</api:keyword><api:keyword scheme="mesh">Adenocarcinoma</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Aprotinin</api:keyword><api:keyword scheme="mesh">Collagen</api:keyword><api:keyword scheme="mesh">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh">Matrix Metalloproteinase Inhibitors</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Mice, Nude</api:keyword><api:keyword scheme="mesh">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh">Phenylalanine</api:keyword><api:keyword scheme="mesh">Plasminogen</api:keyword><api:keyword scheme="mesh">Plasminogen Activators</api:keyword><api:keyword scheme="mesh">Protease Inhibitors</api:keyword><api:keyword scheme="mesh">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword><api:keyword scheme="mesh">Tumor Cells, Cultured</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.62</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record><api:record format="native" id="240906" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000083973200001" last-modified-when="2024-03-14T05:39:47.093+00:00"><api:citation-count>33</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krüger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000083973200001&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">260VB</api:identifier><api:identifier scheme="pubmed">10628317</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANTICANCER RESEARCH</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>serine protease</api:keyword><api:keyword>matrix metalloproteinase</api:keyword><api:keyword>protease inhibitor</api:keyword><api:keyword>tumor cell invasion</api:keyword><api:keyword>Aprotinin</api:keyword><api:keyword>Batimastat</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells &lt;i&gt;in vivo&lt;/i&gt;</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record><api:record format="native" id="23766" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000083973200001" last-modified-when="2014-07-25T11:05:11.6+01:00"><api:citation-count>23</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Della Porta</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Soeltl</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Krell</api:last-name><api:initials>HW</api:initials><api:first-names>HW</api:first-names><api:separate-first-names><api:first-name>H</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Collins</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>O'Donoghue</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Schmitt</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Kruger</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0250-7005</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5B</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANTICANCER RES</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>serine protease</api:keyword><api:keyword>matrix metalloproteinase</api:keyword><api:keyword>protease inhibitor</api:keyword><api:keyword>tumor cell invasion</api:keyword><api:keyword>Aprotinin</api:keyword><api:keyword>Batimastat</api:keyword><api:keyword>IV COLLAGENASE ACTIVITY</api:keyword><api:keyword>PLASMINOGEN-ACTIVATOR</api:keyword><api:keyword>BASEMENT-MEMBRANE</api:keyword><api:keyword>TUMOR INVASION</api:keyword><api:keyword>SYNTHETIC INHIBITOR</api:keyword><api:keyword>UROKINASE RECEPTOR</api:keyword><api:keyword>ANTITUMOR-ACTIVITY</api:keyword><api:keyword>PROGNOSTIC IMPACT</api:keyword><api:keyword>METASTASIS</api:keyword><api:keyword>CANCER</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3809</api:begin-page><api:end-page>3816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>19</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adenocarcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aprotinin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Collagen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Matrix Metalloproteinase Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mice, Nude</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Phenylalanine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Plasminogen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Plasminogen Activators</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Protease Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Thiophenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Tumor Cells, Cultured</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Tumor Cells, Cultured</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mice, Nude</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adenocarcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Thiophenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Collagen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Plasminogen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Plasminogen Activators</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Phenylalanine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aprotinin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Protease Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Matrix Metalloproteinase Inhibitors</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Ovarian Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">2.1 Biological and endogenous factors</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">2 Aetiology</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adenocarcinoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aprotinin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Collagen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Esophageal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Matrix Metalloproteinase 2</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Matrix Metalloproteinase 9</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Matrix Metalloproteinase Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mice, Nude</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasm Invasiveness</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasm Metastasis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasm Transplantation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Ovarian Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Phenylalanine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Plasminogen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Plasminogen Activators</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Protease Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Serine Proteinase Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Thiophenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Tumor Cells, Cultured</api:keyword><api:keyword origin="record-data" source="wos-lite">serine protease</api:keyword><api:keyword origin="record-data" source="wos-lite">matrix metalloproteinase</api:keyword><api:keyword origin="record-data" source="wos-lite">protease inhibitor</api:keyword><api:keyword origin="record-data" source="wos-lite">tumor cell invasion</api:keyword><api:keyword origin="record-data" source="wos-lite">Aprotinin</api:keyword><api:keyword origin="record-data" source="wos-lite">Batimastat</api:keyword><api:keyword origin="record-data" source="wos">serine protease</api:keyword><api:keyword origin="record-data" source="wos">matrix metalloproteinase</api:keyword><api:keyword origin="record-data" source="wos">protease inhibitor</api:keyword><api:keyword origin="record-data" source="wos">tumor cell invasion</api:keyword><api:keyword origin="record-data" source="wos">Aprotinin</api:keyword><api:keyword origin="record-data" source="wos">Batimastat</api:keyword><api:keyword origin="record-data" source="wos">IV COLLAGENASE ACTIVITY</api:keyword><api:keyword origin="record-data" source="wos">PLASMINOGEN-ACTIVATOR</api:keyword><api:keyword origin="record-data" source="wos">BASEMENT-MEMBRANE</api:keyword><api:keyword origin="record-data" source="wos">TUMOR INVASION</api:keyword><api:keyword origin="record-data" source="wos">SYNTHETIC INHIBITOR</api:keyword><api:keyword origin="record-data" source="wos">UROKINASE RECEPTOR</api:keyword><api:keyword origin="record-data" source="wos">ANTITUMOR-ACTIVITY</api:keyword><api:keyword origin="record-data" source="wos">PROGNOSTIC IMPACT</api:keyword><api:keyword origin="record-data" source="wos">METASTASIS</api:keyword><api:keyword origin="record-data" source="wos">CANCER</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0250-7005" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973579" title="Anticancer Research"><api:records><api:record source-name="summary"><api:title>Anticancer Research</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/714/relationships"/></api:object></api:result></api:response>